Our Science: Advancing Safe and Proven Pain Therapeutics

At C-Flow Labs, we are redefining how chronic pain is treated — through precision, safety, and scientific validation. Our mission is to bring evidence-based intrathecal therapies to patients who need lasting, controlled pain relief without compromise. By combining pharmaceutical innovation with deep clinical expertise, we aim to transform a proven but underutilized treatment modality into a scalable, regulated, and life-changing medical solution.

Chronic pain affects more than 49 million people in the United States, representing one of the largest and most persistent medical challenges today. While implantable intrathecal pumps are an established and effective interventional therapy, their potential remains vastly underutilized.

Currently, approximately 120,000 patients in the U.S. are treated with implanted pain pumps. However, fewer than 8% of applicable prescriptions meet approved, on-label indications and dosage criteria. This gap limits the ability to promote, expand, and rigorously study these therapies — leaving a large portion of patients without access to consistent, evidence-based treatment options.

C-Flow Labs is addressing this critical gap by developing on-label drug formulations specifically designed for continuous intrathecal delivery. Our goal is to enhance patient safety, regulatory compliance, and clinical reproducibility through evidence-driven therapeutics supported by randomized clinical trials.

By establishing validated formulations and generating pivotal data, C-Flow Labs is creating a new standard of care in intrathecal therapy while building robust regulatory and competitive barriers that protect long-term innovation.